Study Summary
This trial looks at how well patients stick to their medication plan when given text reminders and/or phone counseling.
Eligible Conditions
- Stage 1 Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer
- HER2 Negative Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Breast Cancer
- Stage 2 Breast Cancer
Video Summary
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: At 24 months post-randomization
At 12 months post-randomization
Endocrine therapy (ET) adherence at 12 months post-randomization
At 24 months post-randomization
Endocrine therapy (ET) adherence at 24 months post-randomization
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Side Effects for
Arm II (gp100 Antigen in Montanide IDA-51 and Aldesleukin)
48%Blood or bone marrow
42%Metabolic or laboratory-testing result
40%Hepatic
36%General
28%Constitutional symptoms
26%Neurologic
22%Pulmonary
21%Gastrointestinal
19%Renal or genitourinary
19%Arrhythmia
13%Pain
8%Infection or febrile neutropenia
7%Skin
7%Musculoskeletal
2%Death
Trial Design
4 Treatment Groups
Arm IV (enhanced usual care)
1 of 4
Arm II (MI)
1 of 4
Arm III (TMR + MI)
1 of 4
Arm I (TMR)
1 of 4
Active Control
Experimental Treatment
1180 Total Participants · 4 Treatment Groups
Primary Treatment: Quality-of-Life Assessment · No Placebo Group · Phase 3
Arm II (MI)Experimental Group · 4 Interventions: Motivational Interviewing, Questionnaire Administration, Quality-of-Life Assessment, Educational Intervention · Intervention Types: Behavioral, Other, Other, Other
Arm III (TMR + MI)Experimental Group · 5 Interventions: Text Message-based Navigation Intervention, Motivational Interviewing, Questionnaire Administration, Quality-of-Life Assessment, Educational Intervention · Intervention Types: Other, Behavioral, Other, Other, Other
Arm I (TMR)Experimental Group · 4 Interventions: Text Message-based Navigation Intervention, Questionnaire Administration, Quality-of-Life Assessment, Educational Intervention · Intervention Types: Other, Other, Other, Other
Arm IV (enhanced usual care)ActiveComparator Group · 4 Interventions: Best Practice, Questionnaire Administration, Quality-of-Life Assessment, Educational Intervention · Intervention Types: Other, Other, Other, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Motivational Interviewing
2020
Completed Phase 3
~9380
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 24 months post-randomization
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,085 Previous Clinical Trials
41,140,283 Total Patients Enrolled
Alliance for Clinical Trials in OncologyLead Sponsor
504 Previous Clinical Trials
215,764 Total Patients Enrolled
Katherine E. Reeder-Hayes, MDStudy ChairUniversity of North Carolina, Chapel Hill
Eligibility Criteria
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Patient is NOT to be deemed ineligible during the recruitment process if they do not have a smart phone.
You have received cancer-directed surgery, and/or completed all other adjuvant therapy, except reconstruction.
Who else is applying?
What state do they live in?
| California | 100.0% |
How old are they?
| 65+ | 100.0% |
What site did they apply to?
| UCSF Cancer Center - Berkeley | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 100.0% |
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments